Miriam Sánchez-Escamilla

Miriam Sánchez-Escamilla

Auto-generated profile, based on publicly available information

Miriam Sánchez-Escamilla

Hematology Department, Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Blood
Verified
Journal Article
Open access
MPMartina Pennisi
Martina Pennisi
MSMiriam Sanchez-Escamilla
Miriam Sanchez-Escamilla
JFJessica Flynn
Jessica Flynn
MMMolly A. Maloy
Molly A. Maloy
MSMari Lynne Silverberg
Mari Lynne Silverberg
MPMiguel-Angel Perales
Miguel-Angel Perales
Introduction Chimeric Antigen Receptor (CAR) T cells are associated with unique toxicities, including cytokine release syndrome (CRS) and immune effector cells-associated neurotoxicity syndrome (ICANS). Patients (pts) with severe CRS and ICANS exhibit hemodynamic instability and coagulopathy with evidence of endothelial activation and increased blood brain barrier permeability. Increases in inflammatory cytokines and biomarkers of endothelial activation in serum and CSF have been associated with severe CRS and ICANS. The EASIX (Endothelial Activation and Stress Index) score [lactate dehydrogenase (LDH) (U/L) × creatinine (mg/dl) / platelets (PLT) (109 cells/L)] correlates with severe fluid overload and survival in allogeneic transplant pts. Elevated LDH and low PLT levels have been associated with severe ICANS development, and high IL-6 levels are seen in severe CRS and ICANS. We hypothesized that the EASIX and a newly proposed version of it, the modified-EASIX (mEASIX), in which creatinine is replaced by CRP (mg/dL) as an easily available surrogate for IL6, would be associated with CRS and ICANS in CAR T cells pts. Methods We analyzed 2 different populations of adult CAR T cells pts treated at our institution: 1) B-cell acute lymphoblastic leukemia (B-ALL) pts treated with CD1928z CAR T cells from 2010 to 2016 (NCT01044069), and 2) aggressive diffuse large B-cell lymphoma (DLBCL) pts treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after FDA approval starting from 2018. EASIX and mEASIX scores were calculated for each patient daily from start of lymphodepletion conditioning to day +14. A log transformation using base 2 (log2) was applied to all EASIX/mEASIX variables to reduce skew. CRS and ICANS were graded according to the ASTCT grading system. Results 87 pts, B-ALL (n=53) and DLBCL (n=34), were analyzed. According to ASTCT grading, 83% (72/87) experienced CRS and 54% (47/87) developed ICANS, grade ≥3 in 23% (20/87) and 40% (35/87) of pts, respectively. When analyzed by disease, CRS and ICANS rates were 87% (46/53) and 55% (29/53) for B-ALL and 76% (26/34) and 53% (18/34) for DLBCL, respectively. CRS and ICANS were grade ≥3 in 28% (15/53) and 45% (24/53) of B-ALL pts and in 15% (5/34) and 32% (11/34) of DLBCL pts, respectively. Median time of onset of CRS after CAR T cell infusion was day +2 and median onset of ICANS was day +6 for the overall population and the subgroups. High EASIX and mEASIX scores at start of conditioning were both associated with development of any grade CRS [OR=1.81 (95% CI 1.09-3.36) p=0.038 and OR=1.94 (95% CI 1.32-3.38) p=0.005] and grade ≥3 CRS [OR=1.47 (95% CI 1.05-2.29) p=0.049 and OR=1.34 (95% CI 1.07-1.80) p=0.024], respectively (Table). Following CAR T cell infusion, high scores of both EASIX [OR=1.60 (95% CI 1.12-2.43) p=0.017] and mEASIX [OR=1.32 (95% CI 1.07-1.69) p=0.014] on day +1 were associated with development of grade ≥3 CRS. Moreover, both high EASIX [OR=1.43 (95% CI 1.08-1.96) p=0.018] and mEASIX [OR=1.29 (95% CI 1.07-1.60) p=0.010] scores on day +3 were associated with grade ≥3 ICANS. When analyzed by disease, results were confirmed for severe CRS and ICANS in B-ALL patients, while in the DLBCL group only mEASIX at start of conditioning and at day +1 was associated with development of any grade CRS. EASIX and mEASIX scores were not associated with response rates to CAR T cells therapy. Conclusions EASIX and mEASIX scores calculated at baseline (before lymphodepletion) are associated with development of CRS and severe CRS. Moreover, both high EASIX and mEASIX scores on day +1 and day +3 are associated with occurrence of grade ≥3 CRS and grade ≥3 ICANS, respectively. We conclude that EASIX and mEASIX, as markers of endothelial damage and inflammation, could be useful as early predictors in guiding treatment decisions before the onset of severe symptoms.

10 October 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JDJuan J. Domínguez-García
Juan J. Domínguez-García
MEMiriam Sánchez Escamilla
Miriam Sánchez Escamilla
SGSara García-Ávila
Sara García-Ávila
BPBrenda López Pereira
Brenda López Pereira
GSGuillermo Martín Sánchez
Guillermo Martín Sánchez
LSLucrecia Yáñez San Segundo
Lucrecia Yáñez San Segundo
Allo-HSCT is a potentially curative treatment for hematologic diseases, but long-term quality of life (QoL) remains a concern. Factors like GVHD, comorbidities, and post-transplant complications can impact survivorship. Understanding QoL in long-term survivors is key to improving care strategies. This observational study included allo-HSCT patients aged ≥18 years, transplanted between January 2010 and December 2015. QoL was assessed by telephone using FACT-BMT and EQ-5D-5L, along with clinical data. Statistical analyses examined associations between QoL and clinical factors. Sixty-seven long-term survivors participated (median follow-up: 7 years). The mean FACT-BMT score was 115.2/148, indicating generally good QoL. However, patients with active GVHD showed reduced physical and emotional functioning. Stem cell source also influenced specific FACT-BMT subscores. Long-term QoL after allo-HSCT is generally favorable, but physical and emotional challenges persist, especially with active GVHD. Targeted interventions and proactive management are crucial to improving overall survivorship care.

9 July 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
MBMa Aránzazu Bermúdez
Ma Aránzazu Bermúdez
OPOscar M. Pello
Oscar M. Pello
MSMiriam Sánchez-Escamilla
Miriam Sánchez-Escamilla
SVSara Vallejo-Díez
Sara Vallejo-Díez
MFMarta Fernández-Martínez
Marta Fernández-Martínez
Enrique M. OcioEnrique M. Ocio
Enrique M. Ocio

17 July 2026 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
APAriadna Pérez-Martínez
Ariadna Pérez-Martínez
MCMónica Cabrero
Mónica Cabrero
JMJuan Montoro
Juan Montoro
MSMiriam Sánchez-Escamilla
Miriam Sánchez-Escamilla
MCMaría Ángeles Cuesta
María Ángeles Cuesta
CSCarlos Solano
Carlos Solano

28 August 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JCJ.M. Cerezo-Martin
J.M. Cerezo-Martin
LSL. Yañez San-Segundo
L. Yañez San-Segundo
JBJ. Bannatyne
J. Bannatyne
SFS. Fernández-Luis
S. Fernández-Luis
MSM. Sánchez-Escamilla
M. Sánchez-Escamilla
MBM.A. Bermúdez
M.A. Bermúdez